Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Smac mimetics as new cancer therapeutics.

Chen DJ, Huerta S.

Anticancer Drugs. 2009 Sep;20(8):646-58. doi: 10.1097/CAD.0b013e32832ced78. Review.

PMID:
19550293
2.

[Role of mitochondrial protein Smac/Diablo in regulation of apoptotic pathways].

Korga A, Korobowicz E, Dudka J.

Pol Merkur Lekarski. 2006 May;20(119):573-6. Review. Polish.

PMID:
16875166
3.

Smac/DIABLO and colon cancer.

Anguiano-Hernandez YM, Chartier A, Huerta S.

Anticancer Agents Med Chem. 2007 Jul;7(4):467-73. Review.

PMID:
17630921
4.

Role of Smac/DIABLO in cancer progression.

Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J.

J Exp Clin Cancer Res. 2008 Sep 26;27:48. doi: 10.1186/1756-9966-27-48. Review.

5.

Smac mimetics as IAP antagonists.

Fulda S.

Semin Cell Dev Biol. 2015 Mar;39:132-8. doi: 10.1016/j.semcdb.2014.12.005. Review.

PMID:
25550219
6.

Molecular pathways: targeting death receptors and smac mimetics.

Fulda S.

Clin Cancer Res. 2014 Aug 1;20(15):3915-20. doi: 10.1158/1078-0432.CCR-13-2376. Review.

7.

Small-molecule SMAC mimetics as new cancer therapeutics.

Bai L, Smith DC, Wang S.

Pharmacol Ther. 2014 Oct;144(1):82-95. doi: 10.1016/j.pharmthera.2014.05.007. Review.

8.

Promises and Challenges of Smac Mimetics as Cancer Therapeutics.

Fulda S.

Clin Cancer Res. 2015 Nov 15;21(22):5030-6. doi: 10.1158/1078-0432.CCR-15-0365. Review.

9.

Mitochondria as therapeutic targets for cancer chemotherapy.

Galluzzi L, Larochette N, Zamzami N, Kroemer G.

Oncogene. 2006 Aug 7;25(34):4812-30. Review.

PMID:
16892093
10.

Smac: Its role in apoptosis induction and use in lung cancer diagnosis and treatment.

Qin S, Yang C, Li S, Xu C, Zhao Y, Ren H.

Cancer Lett. 2012 May 1;318(1):9-13. doi: 10.1016/j.canlet.2011.12.024. Review.

PMID:
22227574
11.

Smac mimetics and TNFalpha: a dangerous liaison?

Wu H, Tschopp J, Lin SC.

Cell. 2007 Nov 16;131(4):655-8. Review.

12.
13.

The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer.

Nachmias B, Ashhab Y, Ben-Yehuda D.

Semin Cancer Biol. 2004 Aug;14(4):231-43. Review.

PMID:
15219616
14.

Small-molecule pan-IAP antagonists: a patent review.

Flygare JA, Fairbrother WJ.

Expert Opin Ther Pat. 2010 Feb;20(2):251-67. doi: 10.1517/13543770903567077. Review.

PMID:
20100005
15.

Anti-tumor therapeutic molecules that target the programmed cell death machinery.

Ivanovska I, Muhoro CN, Irusta PM.

Mini Rev Med Chem. 2006 Sep;6(9):1033-42. Review.

PMID:
17018002
16.

Inhibitor of apoptosis proteins as targets for anticancer therapy.

Fulda S.

Expert Rev Anticancer Ther. 2007 Sep;7(9):1255-64. Review.

PMID:
17892425
17.

Combinatorial cancer immunotherapy strategies with proapoptotic small-molecule IAP antagonists.

Beug ST, Conrad DP, Alain T, Korneluk RG, Lacasse EC.

Int J Dev Biol. 2015;59(1-3):141-7. doi: 10.1387/ijdb.150084el. Review.

PMID:
26374535
18.

[Advancement of studies on second mitochondrial activator of caspase].

Zhao Z, Huang R, Kuang A.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2013 Jun;30(3):666-9. Review. Chinese.

PMID:
23865339
19.

Small molecule inhibitor of apoptosis proteins antagonists: a patent review.

Hird AW, Aquila BM, Hennessy EJ, Vasbinder MM, Yang B.

Expert Opin Ther Pat. 2015 Jul;25(7):755-74. doi: 10.1517/13543776.2015.1041922. Review.

PMID:
25980951
20.

Apoptosis in the treatment of cancer: a promise kept?

Meng XW, Lee SH, Kaufmann SH.

Curr Opin Cell Biol. 2006 Dec;18(6):668-76. Review.

PMID:
17049222
Items per page

Supplemental Content

Support Center